ESMO 2026 has ended. This guide stays up as the record of who was there. Next: ESMO 2027, Sep 17–21, 2027 in Barcelona
Vall d'Hebron Institute of Oncology (VHIO) at ESMO 2026
Oct 23–27, 2026 Madrid, Spain ~37k attendees Website
Vall d'Hebron Institute of Oncology (VHIO) takes part in 29 sessions at ESMO 2026 in Madrid. Its program spans cancer biomarkers and treatment across several tumour types. Topics include tracking tumour DNA over time, identifying genomic changes as cancer progresses, and matching therapies to findings such as HER2 expression.
| Organization | ESMO 2026 Attendance |
|---|---|
Vall d'Hebron Institute of Oncology (VHIO) Barcelona, Spain | |
Translational cancer research institute on the campus of Vall d'Hebron University Hospital in Barcelona, Spain, running early-phase trials. | Poster Fri Oct 23 13:00–15:00 Poster Fri Oct 23 13:00–15:00 Digital Ki67 correlation with endopredict (EP) supports lower than conventional Ki67 cutoff to distinguish luminal-like subtypes in early lobular breast cancer (eLBC) Breast cancerBiomarkers & precision oncology Poster Fri Oct 23 13:00–15:00 Functional and quantitative characterization of KRAS-associated variants of uncertain significance in pancreatic cancer Gastrointestinal cancersBiomarkers & precision oncology Poster Fri Oct 23 13:00–15:00 Talk Fri Oct 23 13:30 Chair Fri Oct 23 13:30–14:45 Talk Fri Oct 23 13:50–14:05 Medical oncology perspective Breast cancer Abstract Fri Oct 23 14:15–14:25 Poster Fri Oct 23 15:15–16:00 A pan-cancer analysis of serial biopsies for emerging ESCAT I alterations at disease progression Gastrointestinal cancersLung & thoracic cancersBreast cancer Poster Fri Oct 23 15:15–16:00 Beyond HER2 IHC: ERBB2 RNA-ISH stratifies benefit from T-DXd combinations Gastrointestinal cancersBreast cancerBiomarkers & precision oncology Poster Fri Oct 23 15:15–16:00 Poster Fri Oct 23 15:15–16:00 Longitudinal ctDNA monitoring and radiological response to targeted therapies (TT) in early-phase clinical trials (EPCT) Biomarkers & precision oncology Poster Fri Oct 23 15:15–16:00 Real-world outcomes of larotrectinib in solid tumors with tropomyosin receptor kinase fusion (GETNE S2411 / SPAINTRK) Sarcoma, CNS, head & neck and rare cancersLung & thoracic cancersBreast cancer Poster Fri Oct 23 15:15–16:00 Chair Fri Oct 23 16:15–17:45 Raising the bar for tumor-agnostic studies Biomarkers & precision oncology Chair Fri Oct 23 16:15–17:45 The evolving standards in the management of chronic lymphocytic leukemia Haematological malignancies Talk Fri Oct 23 17:15–17:35 From hematologic success to solid tumor challenges: CAR-T therapy and T-cell transformation risk Haematological malignancies Chair Sat Oct 24 08:30–10:00 Metastases: Understanding and targeting cancer spread Biomarkers & precision oncology Talk Sat Oct 24 08:30–08:50 Understanding the genomic landscape of metastatic cancer and its therapeutic potential Biomarkers & precision oncology Poster Sat Oct 24 12:00–12:45 An investigator-initiated first-in-human phase I study of autologous p95HER2.CAR-TECH2Me T cells in patients with HER2-positive advanced solid tumors: CATHERINE Gastrointestinal cancersGynaecological cancersBreast cancer Poster Sat Oct 24 12:00–12:45 Clinical and molecular characterization of MTAP/CDKN2A/B-loss glioblastoma in an NGS-profiled institutional cohort Sarcoma, CNS, head & neck and rare cancersBiomarkers & precision oncology Poster Sat Oct 24 12:00–12:45 Clinical and molecular landscape of CDK4-Amplified IDH-wildtype glioblastoma in a real-world multicentric cohort Sarcoma, CNS, head & neck and rare cancersBiomarkers & precision oncology Poster Sat Oct 24 12:00–12:45 Clinical utility of itRECIST assessment to refine patient and injected lesion selection in human intratumoral immunotherapy (HIT-IT) trials in solid tumors Gastrointestinal cancersMelanoma & skin cancersSarcoma, CNS, head & neck and rare cancers Poster Sat Oct 24 12:00–12:45 RNA sequencing–based prognostic signatures in HR+/HER2− advanced breast cancer treated with CDK4/6 inhibitors: A translational analysis of the SOLTI-1801 CDK-PREDICT study Breast cancerBiomarkers & precision oncology Poster Sat Oct 24 12:00–12:45 Second-line treatment of glioblastoma in real-world practice: A multicentric cohort analysis Sarcoma, CNS, head & neck and rare cancers Poster Sat Oct 24 12:00–12:45 Spatial single-cell profiling of tumor phenotypic remodeling and immune engagement during HER2 blockade in HER2-positive breast cancer Breast cancerBiomarkers & precision oncology Poster Sat Oct 24 12:00–12:45 Tuvusertib in recurrent IDH and ATRX mutant astrocytoma: Design of the phase 2 GEINO-2401 / TUVASTRAT study Sarcoma, CNS, head & neck and rare cancers Abstract Sat Oct 24 15:37–15:47 Satellite Sat Oct 24 19:23–19:58 Navigating the NET treatment journey Genitourinary cancersSarcoma, CNS, head & neck and rare cancers Talk Sun Oct 25 08:35–08:55 Talk Sun Oct 25 10:15–10:30 Talk Sun Oct 25 11:00–11:15 Advanced/metastatic prostate cancer: Case presentation Breast cancerGenitourinary cancers Poster Sun Oct 25 12:00–12:45 Microbial interactions signatures as non-invasive tool for early CRC detection Gastrointestinal cancersBiomarkers & precision oncology Chair Sun Oct 25 14:45–16:15 Toxicities of immunotherapies beyond immune checkpoints Nursing & supportive care Talk Sun Oct 25 15:05–15:25 Current landscape of the use of radioligands in gastroenteropancreatic Neuroendocrine neoplasms Sarcoma, CNS, head & neck and rare cancers Talk Sun Oct 25 15:15–15:30 Chair Mon Oct 26 08:30–10:00 Rapid oral: Sarcoma Sarcoma, CNS, head & neck and rare cancers Abstract Mon Oct 26 09:12–09:24 Invited Discussant 3720RO, 3721RO and 3722RO Sarcoma, CNS, head & neck and rare cancers Chair Mon Oct 26 10:15–11:45 Abstract Mon Oct 26 11:00–11:05 Talk Mon Oct 26 15:15–15:30 |
Find decision makers at Vall d'Hebron Institute of Oncology (VHIO)
Tell us what you sell and we’ll find the people at Vall d'Hebron Institute of Oncology (VHIO) most likely to buy it.
- Who to contact
- Their contact info
- What to say
- Free, no sign-up
Not affiliated with or endorsed by the European Society for Medical Oncology. Submit a correction